Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic or Locally Advanced NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchEnded earlyNCT03454243
What this trial is testing

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumors
Hoffmann-La Roche 1
Testing effectiveness (Phase 2)Looking for participantsNCT07486817
What this trial is testing

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Who this might be right for
Lung Cancer, Non-squamous, Non-small Cell
Boehringer Ingelheim 60
Large-scale testing (Phase 3)Study completedNCT00080340
What this trial is testing

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Carcinoma
Telik 520
Early research (Phase 1)Ended earlyNCT06032936
What this trial is testing

BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations

Who this might be right for
NSCLC
LianBio LLC 4
Post-approval studies (Phase 4)Looking for participantsNCT07357597
What this trial is testing

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Who this might be right for
Stomatitis
AstraZeneca 100
Large-scale testing (Phase 3)Ended earlyNCT01244191
What this trial is testing

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Who this might be right for
Non Squamous, Non-small-cell Lung Cancer
Daiichi Sankyo 1,048
Not applicableStudy completedNCT02991274
What this trial is testing

ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

Who this might be right for
Locally Advanced or Metastatic EGFR(+) NSCLC Patients
AstraZeneca 897
Testing effectiveness (Phase 2)Study completedNCT00191490
What this trial is testing

Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 162
Large-scale testing (Phase 3)Study completedNCT01183858
What this trial is testing

Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 315
Early research (Phase 1)Study completedNCT03468426
What this trial is testing

Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Who this might be right for
Non-squamous, Non-Small-Cell Lung CancerNeoplasms
Boehringer Ingelheim 252
Testing effectiveness (Phase 2)Study completedNCT03909971
What this trial is testing

Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 109
Testing effectiveness (Phase 2)Ended earlyNCT02387216
What this trial is testing

MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Who this might be right for
Non-Small Cell Lung CancerNSCLCAdenocarcinoma+1 more
Elevation Oncology 153
Not applicableLooking for participantsNCT07096258
What this trial is testing

EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Hedera Dx SA 1,000
Large-scale testing (Phase 3)Active Not RecruitingNCT05668988
What this trial is testing

DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Who this might be right for
Non-small Cell Lung Cancer
Dizal Pharmaceuticals 324
Testing effectiveness (Phase 2)Active Not RecruitingNCT03225664
What this trial is testing

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+7 more
M.D. Anderson Cancer Center 37
Not applicableLooking for participantsNCT06809764
What this trial is testing

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

Who this might be right for
Non-small Cell Lung Cancer
Daiichi Sankyo 150
Early research (Phase 1)WithdrawnNCT04958967
What this trial is testing

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc.
Early research (Phase 1)Looking for participantsNCT07540572
What this trial is testing

Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Who this might be right for
ER+, HER 2- Breast CancerNon-small Cell Lung Cancer (NSCLC)Castration-resistant Prostate Cancer (CRPC)+1 more
IDEAYA Biosciences 160
Testing effectiveness (Phase 2)Study completedNCT01204697
What this trial is testing

Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 74
Large-scale testing (Phase 3)Study completedNCT00257608
What this trial is testing

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

Who this might be right for
Non-Small Cell Lung Cancer
Genentech, Inc. 1,145
Next Page